PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions

DRUG: Tadalafil
BIOLOGICAL: Anti-MUC1 Vaccine
BIOLOGICAL: Anti-Influenza Vaccine
OTHER: Tadalafil Placebo
OTHER: Anti-MUC1 Vaccine Placebo
OTHER: Standard of Care Treatment
OTHER: Anti-Influenza Vaccine Placebo

Sponsor

Donald T. Weed, MD, FACS